The US Food and Drug Administration has approved three generic versions of Swiss drugmaker Novartis’ top-selling multiple sclerosis (MS) medicine Gilenya, reports Reuters Health. The approval allows HEC Pharm Co Ltd, Biocon Ltd and Sun Pharmaceutical Industries Ltd to produce the drug for the treatment of relapsing forms of MS in adult patients.
The report says the Novartis was defending patents on Gilenya in the US to block generic rivals. Earlier in June, US federal court order had prevented rival generic makers from selling versions of Gilenya in the US.
[link url="https://www.reuters.com/article/us-novartis-generics/u-s-fda-approves-generic-versions-of-novartis-blockbuster-ms-treatment-idUSKBN1Y92O1"]Reuters Health report[/link]